Day

December 12, 2017
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus. “This is an exciting development...
With calls for applications for two major thematic grants, the Lundbeck Foundation is ready to provide funding of up to 250 million Danish kroner for brain research. The larger of the two is aimed at personalised medicine, supporting national strategy in this field. Brain disorders cost society more than cancer, diabetes and cardiovascular disease together....